{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106087","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.790047+00:00","generated_at":"2026-06-10T05:36:59.348442+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TriSalus enters $30M standby equity purchase agreement with Yorkville; authorizes up to $4M warrant repurchase","bullets":["Entered Standby Equity Purchase Agreement to sell up to $30M common stock to Yorkville at 96-97% of VWAP.","Paid $25,000 structuring fee and $300,000 commitment fee; registration statement required before sales.","Board authorized repurchase of publicly-held warrants for up to $4 million.","Advances capped by 4.99% ownership limit and 19.99% exchange cap on outstanding stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106087","json":"https://secwatch.observer/filing/0001104659-23-106087.json","markdown":"https://secwatch.observer/filing/0001104659-23-106087.md","text":"https://secwatch.observer/filing/0001104659-23-106087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923106087/0001104659-23-106087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923106087/tm2327123d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:36:59.348442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66a01333c46631a6d62da7af7a9524b396291ac0","claim":"TriSalus Life Sciences, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) valued at up to $30,000,000 (effective 2023-10-02).","evidence_excerpt":"On October 2, 2023, TriSalus Life Sciences, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923106087/0001104659-23-106087-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"YA II PN, Ltd. (Yorkville)"},{"label":"Value","value":"up to $30,000,000"},{"label":"Effective","value":"2023-10-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}